As the global population experiences unprecedented gains in longevity, the biological trajectory of male senescence has emerged as a central frontier in endocrinology, geroscience, and behavioral medicine. Often colloquially termed the "male menopause," andropause represents a complex, insidious clinical and biochemical syndrome characterized by age-related systemic decline in circulating androgens. Unpacking the neurobiological, physical, and psychological facets of this transition provides vital insights into the maintenance of vitality, sexual health, and metabolic equilibrium throughout the male lifespan.
Andropause
1. Concise Definition
Andropause, scientifically designated as late-onset hypogonadism (LOH), is a clinical and biochemical syndrome occurring in aging men characterized by typical physiological, psychological, and sexual symptoms paired with a documented deficiency in serum androgen concentrations. Unlike female menopause, which is marked by an abrupt, universal cessation of gonadal germ cell production and drastic estradiol depletion, andropause features an insidious, gradual, and highly variable decline in total and bioavailable testosterone across decades.
The consensus criteria formulated by major endocrine societies mandate that an authentic diagnosis of andropause requires the simultaneous presence of validated clinical manifestations—such as erectile dysfunction, decreased libido, sarcopenia, fatigue, and affective blunting—alongside repeatedly measured subnormal serum testosterone levels collected during early morning fasting states. Consequently, andropause represents both a physiological alteration of the endocrine system and a multifaceted geriatric health construct influenced profoundly by body composition, lifestyle habits, and chronic comorbid illness.
2. Etymology & Linguistic Origin
The term andropause is a modern neoclassical compound derived from two Classical Greek roots: ἀνήρ (anēr, genitive andros, meaning "man" or "male") and παῦσις (pausis, meaning "cessation," "pause," or "stopping"). The lexeme entered medical parlance during the mid-20th century, intentionally coined by clinicians and medical writers to serve as a masculine semantic counterpart to menopause (from Greek mēn, "month," and pausis).
Although the word gained widespread cultural traction throughout the late 1980s and 1990s, medical purists frequently challenge its etymological precision. Because men do not experience a total "pause" or absolute cessation of spermatogenesis or androgen biosynthesis—retaining testicular endocrine activity into extreme advanced age—the international biomedical community generally favors diagnostic designations such as Late-Onset Hypogonadism (LOH), Age-Related Testosterone Deficiency, or Partial Androgen Deficiency of the Aging Male (PADAM).
3. Pronunciation & Grammatical Form
Pronunciation: The standard International Phonetic Alphabet (IPA) transcription of the term is /ˈæn.drə.pɔːz/ in British English and /ˈæn.droʊ.pɑːz/ in American English.
Grammatical Form: The term operates syntactically as an uncountable singular abstract noun. Derived grammatical variations include the adjectival forms andropausal (e.g., "andropausal transition," "andropausal symptomatology") and pre-andropausal. It possesses no established verbal form, although medical sociologists occasionally refer descriptively to individuals as "undergoing andropause."
4. Detailed Conceptual Explanation
To grasp the conceptual scope of andropause, one must examine the baseline endocrine physiology of aging. Beginning around the third to fourth decade of life, circulating concentrations of testosterone in biological males drop at a predictable trajectory of approximately 1% to 2% annually. Concurrently, circulating levels of hepatic-derived sex hormone-binding globulin (SHBG) rise progressively at roughly 1.2% per year. Because SHBG binds circulating testosterone with robust affinity, the fraction of physiologically active hormone—namely free testosterone and albumin-bound testosterone, collectively known as bioavailable testosterone—undergoes an even steeper decrement, often falling by up to 2% to 3% each year.
The etiology of this decline operates via both central and peripheral mechanisms across the hypothalamic-pituitary-gonadal axis. Centrally, the hypothalamic pulse generator displays impaired frequency and amplitude in the release of gonadotropin-releasing hormone (GnRH), coupled with blunted pituitary responsiveness in secreting luteinizing hormone (LH). Peripherally, the testes experience a progressive numerical depletion and architectural degeneration of steroidogenic Leydig cells, accompanied by microvascular sclerosis, decreased perfusion, and reduced responsiveness to LH stimulation. As a result, andropause represents a mixed primary-secondary hypogonadal pattern.
The downstream consequences of this androgen shortfall ripple throughout virtually every physiological compartment. In musculoskeletal tissue, testosterone deficiency drives myocyte apoptosis, reductions in muscle protein synthesis, and uncoupling of bone turnover, facilitating sarcopenia, physical frailty, and osteopenia. Metabolically, low testosterone favors the expansion of visceral adipose tissue, which expresses high levels of the enzyme aromatase; this drives greater conversion of remaining androgens into estrogens, generating a self-perpetuating endocrine feedback loop that exacerbates insulin resistance, dyslipidemia, and systemic pro-inflammatory cytokine secretion.
Neurobehaviorally, testosterone crosses the blood-brain barrier and modulates neurotransmitter systems, including dopaminergic, serotonergic, and noradrenergic circuits. Androgen deficit during late-onset hypogonadism correlates clinically with persistent subjective exhaustion, blunted executive functioning, disrupted slow-wave sleep architecture, affective dysregulation, loss of competitive drive, and increased susceptibility to subclinical or clinical depressive states.
5. Historical Development
The realization that aging males experience gonadal regression has historical roots reaching back to antiquity, but systematic scientific investigation originated in the late 19th century. In 1889, French physiologist Charles-Édouard Brown-Séquard famously announced to the Société de Biologie in Paris that self-injections of aqueous extracts derived from dog and guinea pig testicles yielded dramatic rejuvenation, enhancing his physical stamina and cognitive focus. Although largely propelled by placebo effects, Brown-Séquard's experiments catalyzed modern endocrinology and organotherapy.
During the 1930s and 1940s, biochemists Adolf Butenandt and Leopold Ruzicka synthesized pure crystalline testosterone, enabling controlled clinical observations. In 1939 and 1944, American physician August A. Werner published landmark papers documenting the "male climacteric," identifying a cohort of men presenting with vasomotor flushes, nervous instability, loss of libido, and depression who responded favorably to intramuscular injections of testosterone propionate. In 1944, Carl Heller and Gordon Myers reinforced Werner’s thesis by utilizing urinary gonadotropin assays to differentiate between primary testicular failure and psychological psychoneurosis in aging men.
Throughout the late 20th century, the paradigm evolved through epidemiological methodology. The Massachusetts Male Aging Study (MMAS), initiated in the late 1980s by John B. McKinlay and colleagues, documented population-level age-dependent hormonal shifts, formally disproving the presumption that male androgen production remains stable across life. In the early 2000s, the landmark European Male Ageing Study (EMAS) surveyed over 3,300 men aged 40 to 79 across eight European centers, providing rigorous empirical criteria to distinguish true clinical late-onset hypogonadism from unadulterated chronological senescence.
6. Theoretical Foundations
The academic study of andropause is underpinned by three foundational theoretical paradigms: evolutionary biology, neuroendocrine senescence theory, and the biopsychosocial framework of chronic health.
From an evolutionary perspective, antagonistic pleiotropy theory posits that evolutionary selection favors genes and biological traits that confer high reproductive fitness and anabolic potency during youth, even if those identical pathways produce detrimental phenotypes or degenerative outcomes later in post-reproductive life. Sustaining supraphysiological testosterone levels into old age may theoretically elevate risks of metabolic exhaustion, immunosuppression, and neoplastic proliferation (such as prostate malignancies). Hence, gradual down-regulation of androgenic signaling may have emerged as a protective adaptation to conserve metabolic resources and dampen tissue-specific oncogenic stress.
The neuroendocrine senescence paradigm situates andropause within a coordinated matrix of endocrine pacemakers that shift over time. Rather than operating as an isolated gonadal failure, andropause synchronizes with somatopause (the marked diminution of the growth hormone/insulin-like growth factor-1 axis) and adrenopause (the dramatic attenuation of adrenal dehydroepiandrosterone [DHEA] and its sulfate ester [DHEAS]). This systemic "endocrine pause" reflects an orchestrated reset of neuroendocrine allostasis that shapes somatic integrity.
Finally, modern medicine approaches andropause through a biopsychosocial model. Biological reductions in bioavailable androgens do not dictate clinical outcomes in a vacuum; instead, they interface with psychological coping strategies, marital satisfaction, occupational transitions, retirements, chronic somatic comorbidities (such as type 2 diabetes and hypertension), and societal narratives surrounding masculine virility and aging.
7. Key Components, Types & Dimensions
Andropause presents as a multi-domain clinical entity that spans distinct biological, physical, and psychological symptom clusters:
- Sexual Function Domain: Reductions in the frequency and intensity of morning and nocturnal penile tumescence (NPT), diminished sexual fantasy, decreased spontaneous libido, orgasmic blunting, and varying degrees of erectile dysfunction that frequently prove refractory to phosphodiesterase-5 (PDE-5) inhibitors alone.
- Somatic and Musculoskeletal Domain: Significant depletion of lean muscle mass (sarcopenia), decreases in peak handgrip and functional physical strength, generalized fatigue, reduced exercise tolerance, visceral and central adiposity, progressive loss of bone mineral density culminating in osteopenia or frank osteoporosis, and increased susceptibility to non-traumatic fractures.
- Neuropsychological and Affective Domain: Persistent low mood, dysthymia, irritability, emotional lability, apathy, sleep disturbances (principally non-restorative sleep or insomnia), reduced mental clarity, lapses in spatial and verbal working memory, and diminished subjective well-being.
- Vasomotor and Dermato-trophic Domain: Occasional episodic diaphoresis, night sweats, acute hot flushes reminiscent of female menopausal symptoms (particularly following rapid androgen ablation), reduced axillary and pubic hair density, dry skin, and mild normochromic, normocytic anemia secondary to decreased erythropoietin secretion.
- Biochemical Subtypes: Categorized into Primary Late-Onset Hypogonadism (hypergonadotropic, characterized by subnormal testosterone accompanied by elevated LH and FSH due to testicular failure) and Secondary Late-Onset Hypogonadism (hypogonadotropic, characterized by subnormal testosterone paired with inappropriately normal or suppressed LH and FSH due to hypothalamic-pituitary disruption or visceral metabolic inhibition).
8. Examples & Illustrative Cases
Case 1: Classic Late-Onset Hypogonadism in Metabolic Syndrome. A 54-year-old corporate director presents with a 2-year history of progressive fatigue, diminished mental drive, weight gain localized to the abdomen, and loss of morning erections. Laboratory evaluation reveals a fasting morning total testosterone of 215 ng/dL (reference range: 300–1000 ng/dL) confirmed on a subsequent draw, elevated SHBG, and an inappropriately low-normal LH level (2.1 IU/L). His BMI is 32 kg/m², with elevated fasting glucose and mild hepatic steatosis. This scenario exemplifies secondary andropause driven by central feedback disruption and visceral adiposity-mediated peripheral aromatization.
Case 2: Primary Testicular Senescence. A 72-year-old active, non-obese male reports generalized muscular weakness, profound exhaustion following mild exertion, and a minor-impact wrist fracture. Dual-energy X-ray absorptiometry (DEXA) indicates a lumbar spine T-score of -2.6, denoting osteoporosis. Endocrine assessment demonstrates a total testosterone of 180 ng/dL and a free testosterone level well below the lower threshold of normal, accompanied by elevated LH (14.2 IU/L) and FSH (19.8 IU/L). This case reflects primary, hypergonadotropic andropause resulting from intrinsic age-related Leydig cell depletion and testicular tissue sclerosis.
Case 3: Non-Hypogonadal Symptom Mimicry. A 49-year-old male presents complaining of low energy, sadness, sleep disruption, and reduced sexual enthusiasm, suspecting "andropause." Serum hormone panels, executed across multiple early morning draws, confirm robust total testosterone levels (540 ng/dL and 510 ng/dL) and normal free testosterone. Further psychological and medical screening reveals an emerging major depressive disorder alongside severe obstructive sleep apnea. This case emphasizes the clinical pitfall of misattributing non-specific psychological and lifestyle distress to andropause without rigorous biochemical corroboration.
9. Measurement & Assessment
Accurate clinical identification of andropause demands a standardized, two-tiered diagnostic algorithm that integrates validated psychometric screening questionnaires with stringent laboratory assessments.
Initial symptom burden is frequently screened using standardized questionnaires, including:
- ADAM (Androgen Deficiency in the Aging Male): A 10-item screening tool developed by St. Louis University focusing on libido, energy, strength, and erectile performance. While displaying high sensitivity (~88%), it exhibits low specificity (~30%), meaning positive screens require laboratory verification.
- AMS (Aging Males' Symptoms Scale): A 17-item multidimensional scale evaluating psychological, somatic, and sexual dimensions, useful for quantifying baseline symptom severity and tracking clinical response to intervention.
Biochemical confirmation is essential and must adhere to strict clinical chemistry protocols. Blood samples must be drawn between 7:00 AM and 11:00 AM in a fasting state, capturing the natural circadian peak of testosterone (a rhythm that flattens with advancing age yet remains clinically relevant). Guidelines from the Endocrine Society and the American Urological Association (AUA) dictate the following biochemical pathway:
- Total Serum Testosterone: Measured via equilibrium dialysis or high-accuracy liquid chromatography-tandem mass spectrometry (LC-MS/MS). A diagnosis typically requires at least two separate measurements falling below 300 ng/dL (10.4 nmol/L).
- Free and Bioavailable Testosterone: Indispensable when circulating SHBG levels are altered by age, obesity, liver disease, or thyroid abnormalities. Calculated free testosterone (using the Vermeulen or Sodergard formula) or direct equilibrium dialysis is measured; thresholds below 5 ng/dL (or 220 pmol/L) confirm hypogonadism in symptomatic individuals.
- Gonadotropins (LH and FSH): Assessed to definitively distinguish between primary (testicular) and secondary (hypothalamic/pituitary) etiology.
- Ancillary Biomarkers: Prolactin levels are obtained to rule out hyperprolactinemia or pituitary prolactinomas; serum ferritin to exclude hemochromatosis; complete blood count (hematocrit) to evaluate polycythemia risk prior to therapy; and Prostate-Specific Antigen (PSA) combined with digital rectal examination to screen for underlying prostatic disease.
10. Applications & Practical Significance
The diagnosis and management of andropause holds critical significance across modern urology, endocrinology, primary care, and preventive gerontology. When accurately distinguished from normal physiological aging, targeted interventions yield profound improvements in patient quality of life, physical vitality, and systemic longevity.
The therapeutic mainstay for verified late-onset hypogonadism is Testosterone Replacement Therapy (TRT). Administered through diverse pharmacological modalities—transdermal gels and solutions, subcutaneous or intramuscular depot injections (such as testosterone cypionate, enanthate, or undecanoate), transbuccal systems, and subdermal crystalline pellets—TRT seeks to restore circulating testosterone concentrations back into the mid-normal physiological range for young adult men (typically 450–650 ng/dL). Documented benefits of TRT include improvements in lean body mass, muscular strength, skeletal bone mineral density, nocturnal erections, sexual satisfaction, subjective energy levels, and glycemic control in men with comorbid type 2 diabetes.
Critically, contemporary clinical practice recognizes that pharmacotherapy must be paired with lifestyle interventions. Interventions targeting caloric restriction, reduction of refined carbohydrate intake, and structured resistance training stimulate endogenous androgen axis function, down-regulate systemic inflammation, reduce hepatic SHBG pathology, and directly enhance metabolic status without the potential downfalls of exogenous endocrine suppression.
11. Research & Empirical Evidence
Extensive epidemiological and clinical trial literature has elucidated the mechanisms, prevalence, and therapeutic nuances of andropause. The European Male Ageing Study (EMAS), led by Frederick Wu and published in the New England Journal of Medicine (2010), established that while biochemical testosterone deficiency occurs in up to 17% of older men, true late-onset hypogonadism—defined rigorously by Wu and colleagues as the conjunction of low total and free testosterone alongside at least three cardinal sexual symptoms (poor morning erections, erectile dysfunction, and low sexual desire)—was present in only 2.1% of men aged 40 to 79. The EMAS researchers demonstrated that general somatic and psychological symptoms (e.g., fatigue, depression) showed weak correlations with serum testosterone when sexual symptoms were absent.
In 2016, the National Institutes of Health-sponsored Testosterone Trials (TTrials), spearheaded by Peter J. Snyder and published across several papers in the New England Journal of Medicine and JAMA Internal Medicine, investigated 790 men aged 65 and older with unequivocal hypoandrogenism. The randomized, double-blind, placebo-controlled trial demonstrated that 12 months of testosterone replacement produced clear, statistically significant benefits in sexual desire and erectile function, moderate improvements in walking distance and physical vitality, and modest improvements in mood and depressive symptoms. However, it demonstrated non-significant effects on overall cognitive performance and noted a marked increase in non-calcified coronary artery plaque volume measured by coronary computed tomography angiography, renewing interest in the cardiovascular profiles of aging men on therapy.
Subsequent long-term observational cohorts and large-scale registry data, such as the TRAVERSE trial (Lincoff et al., 2023), assessed the cardiovascular safety of testosterone replacement therapy in middle-aged and older men with hypogonadism and established cardiovascular disease or elevated cardiovascular risk. TRAVERSE revealed that carefully monitored physiological TRT was non-inferior to placebo regarding the incidence of major adverse cardiac events (MACE), providing definitive clarity to decades of clinical debate.
12. Cultural & Cross-Cultural Considerations
The subjective experience, medicalization, and reporting of andropause display stark cross-cultural variability. In Western, industrialized contexts—most notably North America and Western Europe—andropause has historically been heavily medicalized. Driven by high clinical awareness, broad direct-to-consumer advertising, and cultural imperatives emphasizing youthfulness, physical muscularity, and uninterrupted sexual performance, Western males frequently interpret natural age-related somatic dips as pathological states demanding biomedical intervention.
Conversely, comparative cross-cultural studies highlight divergent symptomatology profiles in non-Western populations. In studies conducted across East Asian countries, such as Japan and China, aging males report significantly lower rates of sexual distress, loss of libido, and affective crisis relative to Western cohorts, but report elevated frequencies of somatic discomfort, musculoskeletal stiffness, and non-specific malaise. Scholars attribute these discrepancies partly to sociocultural differences in traditional masculinity, varied dietary inputs (such as higher phytoestrogen and soy intake, or distinct baseline lipid profiles), and cultural philosophies wherein physiological slowing is framed not as a medical pathology, but as an expected, honorable life transition.
13. Criticisms, Debates & Limitations
Despite its clinical codification, andropause remains one of the most vigorously debated constructs in modern medicine. Skeptics, including medical sociologists and critical pharmacologists, have accused the biomedical establishment and pharmaceutical enterprises of "disease mongering"—transforming the natural, non-pathological trajectory of male aging into an artificial endocrine deficiency disease dubbed "Low T" to market hormonal therapeutics.
Major debates center around the following issues:
- Nomenclature Inaccuracy: The medical consensus affirms that andropause is a physiological misnomer. Unlike female menopause, which represents an invariant biological event involving irreversible ovarian follicular exhaustion, male reproductive and steroidogenic capacity declines heterogeneously, with wide swathes of octogenarians retaining healthy circulating testosterone levels and fertile spermatogenesis.
- Causality Dilemma (Chicken or Egg): A primary challenge is unraveling whether hypogonadism causes metabolic decline, obesity, and systemic frailty, or whether accumulated comorbidities (e.g., metabolic syndrome, sleep apnea, vascular disease, sedentary lifestyles) directly suppress hypothalamic-pituitary-gonadal function. Substantial evidence indicates that significant weight loss and bariatric surgery can reverse secondary hypogonadism without administering exogenous testosterone.
- Oncological and Cardiovascular Anxieties: For decades, the long-standing dogma inherited from Charles Huggins' 1941 work posited that exogenous testosterone stimulates the growth of prostate carcinoma. While modern evidence confirms that therapeutic TRT does not induce de novo prostate cancer within physiological ranges (the saturation model proposed by Morgentaler), caution persists regarding occult neoplastic growth, secondary erythrocytosis (hematocrit > 54%), sleep apnea exacerbation, and venous thromboembolic events.
14. Related Terms & Distinctions
To avoid diagnostic confusion, andropause must be carefully distinguished from allied endocrine, physiological, and psychological entities:
- Menopause: The permanent, abrupt cessation of menstruation and ovarian endocrine activity in females, marked by complete germ cell loss and severe estrogen depletion. In contrast, andropause is gradual, non-universal, partial, and permits ongoing gametogenesis.
- Primary Hypogonadism (Hypergonadotropic): Testicular endocrine failure stemming from congenital conditions (such as Klinefelter syndrome) or acquired structural damage (such as bilateral orchitis or radiation exposure). While andropause may contain primary hypogonadal elements, it develops later in life alongside combined neuroendocrine dysregulation.
- Secondary Hypogonadism (Hypogonadotropic): Central impairment originating in the pituitary or hypothalamus (e.g., Kallmann syndrome, pituitary macro-adenomas, severe hyperprolactinemia). Andropause exhibits secondary-like profiles but operates within the broader biological context of senescent aging.
- Somatopause: The age-related decline of the growth hormone (GH) and insulin-like growth factor 1 (IGF-1) somatotropic axis. Although it mirrors andropause chronologically and shares clinical phenotypes (such as sarcopenia and central adiposity), it operates via entirely separate endocrine pathways.
- Adrenopause: The physiological involution of the adrenal zona reticularis, leading to progressive decreases in the output of circulating dehydroepiandrosterone (DHEA) and DHEA-sulfate, occurring in both males and females independently of testicular decline.
- Sarcopenia: The progressive loss of skeletal muscle mass, strength, and function with age. While hypogonadism accelerates sarcopenia, sarcopenia itself is a multi-factorial muscular disorder influenced by physical inactivity, denervation, inadequate protein intake, and chronic inflammation.
15. Summary / Key Takeaways
Andropause, appropriately diagnosed as late-onset hypogonadism, is a nuanced multidimensional condition combining documented age-related biochemical androgen deficiency with explicit clinical symptoms across sexual, somatic, and affective domains. Characterized by an insidious 1% to 2% annual decline in circulating testosterone coupled with an increase in binding globulins from midlife onward, its development is shaped by both primary testicular degradation and central neuroendocrine blunting.
Rigorous diagnosis hinges upon repeated, early morning fasting hormone measurements confirming subnormal bioavailable or total testosterone alongside definitive sexual symptoms, such as erectile dysfunction and loss of libido. While modern pharmacological management through testosterone replacement therapy offers restorative benefits for muscle mass, bone density, energy, and sexual vitality, successful treatment mandates careful patient selection, exclusion of underlying contraindications, and comprehensive integration of lifestyle modifications, resistance exercise, and metabolic disease management.
Ultimately, navigating andropause successfully requires a nuanced understanding that bridges the gap between biological destiny and clinical intervention. By addressing the decline of male androgens through an evidence-based, holistic paradigm, clinicians and individuals can decouple physiological chronological aging from systemic functional decline, supporting sustainable vitality, sexual health, and metabolic balance well into later life.
References
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. https://doi.org/10.1210/jc.2018-00229
- Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., Wang, C., Wolski, K., & Nissen, S. E. (2023). Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine, 389(2), 107–117. https://doi.org/10.1056/NEJMoa2215025
- Morgentaler, A., & Traish, A. M. (2009). Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth. European Urology, 55(2), 310–320. https://doi.org/10.1016/j.eururo.2008.09.024
- Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., Ensrud, K. E., Lewis, C. E., Farrar, J. T., Cella, D., Rosen, R. C., Pahor, M., Crandall, J. P., Molitch, M. E., Resnick, S. M., … Ellenberg, S. S. (2016). Effects of testosterone treatment in older men. New England Journal of Medicine, 374(7), 611–624. https://doi.org/10.1056/NEJMoa1506119
- Wu, F. C., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, P. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., Giwercman, A., Han, T. S., Kula, K., Lean, M. E., Pendleton, N., Punab, M., Vanderschueren, D., Labrie, F., Huhtaniemi, I. T., & EMAS Group. (2010). Identification of late-onset hypogonadism in middle-aged and elderly men. New England Journal of Medicine, 363(2), 123–135. https://doi.org/10.1056/NEJMoa0911101